Naldemedine: A New Option for OIBD

Area of Science:

• Gastroenterology
• Pharmacology
• Pain Management

Background:

• Opioid-induced bowel dysfunction (OIBD) is a prevalent and burdensome complication affecting a significant percentage of patients using opioids for chronic pain.
• OIBD negatively impacts patient quality of life and contributes to increased healthcare costs.
• The persistent use of opioids necessitates effective management strategies for OIBD.

Purpose of the Study:

• To review the pathophysiological mechanisms of OIBD.
• To evaluate available treatments for OIBD, with a focus on peripherally acting mu-opioid receptor antagonists (PAMORAs).
• To discuss the pharmacological properties, clinical efficacy, and side effects of naldemedine for OIBD management.

Main Methods:

• Literature review of OIBD pathophysiology and treatments.
• Analysis of pharmacological data and clinical trial results for naldemedine.
• Discussion of comparative data and considerations for naldemedine versus other PAMORAs.

Main Results:

• Naldemedine demonstrates efficacy in alleviating constipation associated with OIBD.
• Naldemedine is generally well-tolerated and does not appear to affect central analgesia.
• No significant symptoms of opioid withdrawal were observed with naldemedine treatment.

Conclusions:

• Naldemedine represents a valid and effective treatment option for patients suffering from OIBD.
• The drug's favorable tolerability profile and efficacy in managing constipation make it a valuable addition to OIBD treatment strategies.
• Further head-to-head comparisons with other PAMORAs would provide additional insights into its comparative effectiveness.